Neuropace: H.C. Wainwright cuts target price to $12 from $20
NPCE•H.C. Wainwright cut its target price for Neuropace to $12 from $20.
Related News

Shinhan Financial Group swings to three-month separate net profit of KRW 2.98 billion
SHG•

Nakamoto amends at-the-market stock offering agreement for up to $4.99 billion
NAKA•

Western Midstream Partners, LP: Wells Fargo raises target price to $47 from $46
WES•

Rivian: Citigroup cuts target price to $14.5 from $18
RIVN•

Powerus partners with G1 Exploration to commercialize defense and autonomous power technology
PUSA•